National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Meeting, 69125 [E9-30889]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 249 / Wednesday, December 30, 2009 / Notices
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.846, Arthritis,
Musculoskeletal and Skin Diseases Research,
National Institutes of Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and
Musculoskeletal and Skin Diseases;
Notice of Meeting
mstockstill on DSKH9S0YB1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Arthritis and Musculoskeletal
and Skin Diseases Advisory Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Arthritis and
Musculoskeletal and Skin Diseases Advisory
Council.
Date: February 2, 2010.
Open: 8:30 a.m. to 2 p.m.
Agenda: To discuss administrative details
relating to the Council’s business and special
reports.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 6, Bethesda, MD 20892.
Closed: 2 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 6, Bethesda, MD 20892.
Contact Person: Susana Serrate-Sztein, MD,
Director, Division of Skin and Rheumatic
Diseases, NIAMS/NIH, 6701 Democracy
Blvd, Suite 800, Bethesda, MD 20892–4872.
(301) 594–5032. szteins@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
VerDate Nov<24>2008
19:01 Dec 29, 2009
Jkt 220001
Dated: December 18, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–30889 Filed 12–29–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0664]
Medical Device Interoperability; Public
Workshop
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public workshop.
The Food and Drug Administration
(FDA), Center for Devices and
Radiological Health, in co-sponsorship
with Continua Health Alliance and the
Center for Integration of Medicine &
Innovative Technology (CIMIT) is
announcing a public workshop entitled
‘‘Medical Device Interoperability.’’ The
purpose of the workshop is to facilitate
discussion among FDA, industry,
academia, professional societies,
clinical investigators and other
interested parties on issues related to
safe and effective interoperable medical
devices.
Dates and Times: The public
workshop will be held on January 25
and 26, 2010, from 9 a.m. to 5 p.m. and
on January 27, 2010, from 9 a.m. to 12
noon. Participants are encouraged to
arrive early to ensure time for parking
and security screening before the
meeting. Security screening will begin
at 8 a.m. and registration will begin at
8:30 a.m.
Location: The public workshop will
be held at the FDA White Oak Campus,
10903 New Hampshire Ave., Silver
Spring, MD 20993.
Contact Persons: Sandy Weininger,
Center for Devices and Radiological
Health, Food and Drug Administration,
10903 New Hampshire Ave., WO62/rm.
4212, Silver Spring, MD 20993, 301–
796–2582, sandy.weininger@fda.hhs.
gov; or John Murray, Center for Devices
and Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., WO66/rm. 2634, Silver Spring,
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
69125
MD 20993, 301–796–5543,
john.murray@fda.hhs.gov.
Registration: To register for the public
workshop, please visit the following
Web site: https://mdpnp.org/
FDA_Interop_Workshop.php. There is a
registration fee of $500 to attend the
public workshop to cover the expenses
and attendees must register in advance.
The registration process will be handled
by Continua Health Alliance. In person,
attendance is limited to 200
participants.
Registration may be limited to achieve
balanced participation. Upon
registering, you will receive a notice
indicating that your registration has
been received and is pending
confirmation. You will receive an
additional email within 1 week
notifying you if your registration was
accepted or declined. You may also
register to attend the public workshop
via Web cast for a reduced fee.
Non-U.S. citizens are subject to
additional security screening, and they
should register as soon as possible. If
you need special accommodations
because of a disability, please contact
Susana Rosales
(Susana.Rosales@fda.hhs.gov) at least 7
days before the public workshop.
SUPPLEMENTARY INFORMATION:
I. Why Are We Holding This Public
Workshop?
The purpose of the public workshop
is to facilitate discussion among FDA
and other interested parties regarding
the safety and effectiveness of
interoperable medical devices.
II. What Are the Topics We Intend to
Address at the Public Workshop?
We hope to discuss a large number of
issues at the public workshop,
including, but not limited to the
following:
• What are the types of clinical
scenarios that would make use of
medical device interoperability?
• What are the issues associated with
premarket and postmarket studies for
interoperable medical devices?
• What tools (e.g., standards,
guidances) are in place or need to be
developed to assure safety and
effectiveness of interoperable medical
device systems? What issues should
they address?
• What are the risks associated with
medical device interoperability and
‘‘system of systems’’ composing medical
devices?
• What are other issues relevant to
assuring the safety and effectiveness of
interoperable medical devices?
E:\FR\FM\30DEN1.SGM
30DEN1
]]>Agencies
[Federal Register Volume 74, Number 249 (Wednesday, December 30, 2009)]
[Notices]
[Page 69125]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-30889]
[[Page 69125]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and Musculoskeletal and Skin
Diseases; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
National Arthritis and Musculoskeletal and Skin Diseases Advisory
Council.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Arthritis and Musculoskeletal and
Skin Diseases Advisory Council.
Date: February 2, 2010.
Open: 8:30 a.m. to 2 p.m.
Agenda: To discuss administrative details relating to the
Council's business and special reports.
Place: National Institutes of Health, Building 31, 31 Center
Drive, Conference Room 6, Bethesda, MD 20892.
Closed: 2 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Building 31, 31 Center
Drive, Conference Room 6, Bethesda, MD 20892.
Contact Person: Susana Serrate-Sztein, MD, Director, Division of
Skin and Rheumatic Diseases, NIAMS/NIH, 6701 Democracy Blvd, Suite
800, Bethesda, MD 20892-4872. (301) 594-5032. szteins@mail.nih.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
(Catalogue of Federal Domestic Assistance Program Nos. 93.846,
Arthritis, Musculoskeletal and Skin Diseases Research, National
Institutes of Health, HHS)
Dated: December 18, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-30889 Filed 12-29-09; 8:45 am]
BILLING CODE 4140-01-P
